Beijing Aosaikang Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Beijing Aosaikang Pharmaceutical Co., Ltd. carries a market capitalization of 14.09B, placing it among publicly traded companies globally. Its enterprise value stands at 12.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 14.09B |
| Enterprise Value | 12.33B |
Share Statistics
Beijing Aosaikang Pharmaceutical Co., Ltd. currently has 928.16M shares outstanding.
| Shares Outstanding | 928.16M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Beijing Aosaikang Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 59.57. The price-to-sales ratio is 7.83, and the price-to-book ratio stands at 5.36.
| PE Ratio | 59.57 |
| PS Ratio | 7.83 |
| PB Ratio | 5.36 |
| P/TBV Ratio | 6.26 |
| P/FCF Ratio | 68.16 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Beijing Aosaikang Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 60.24 and an EV/FCF ratio of 57.24. The EV/Sales ratio of 6.62 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 60.24 provides insight into valuation relative to core operating earnings.
| EV / Sales | 6.62 |
| EV / EBITDA | 60.24 |
| EV / EBIT | 60.24 |
| EV / FCF | 57.24 |
Financial Position
Beijing Aosaikang Pharmaceutical Co., Ltd. maintains a current ratio of 2.57, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.72, indicating elevated leverage, while an interest coverage ratio of 123.22 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.57 |
| Quick Ratio | 2.13 |
| Debt / Equity | 1.72 |
| Debt / EBITDA | 0.27 |
| Interest Coverage | 123.22 |
Financial Efficiency
Beijing Aosaikang Pharmaceutical Co., Ltd. posts a return on equity of 9.23 and a return on invested capital of 5.81.
| Return on Equity (ROE) | 9.23 |
| Return on Assets (ROA) | 5.96 |
| Return on Invested Capital (ROIC) | 5.81 |
| Return on Capital Employed (ROCE) | 9.90 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.09 |
Taxes
Over the trailing twelve months, Beijing Aosaikang Pharmaceutical Co., Ltd. has paid 19.08M in income taxes, reflecting an effective tax rate of 8.28.
| Income Tax | 19.08M |
| Effective Tax Rate | 8.28 |
Stock Price Statistics
Beijing Aosaikang Pharmaceutical Co., Ltd.'s stock has declined approximately -15.76027% over the past 52 weeks. The 50-day moving average sits at 14.93, while the 200-day moving average is 16.57.
| Beta (5Y) | N/A |
| 52-Week Price Change | -15.76027% |
| 50-Day Moving Average | 14.93 |
| 200-Day Moving Average | 16.57 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Beijing Aosaikang Pharmaceutical Co., Ltd. generated 1.86B in revenue and converted that into 244.69M in net income, yielding earnings per share of 0.23. EBITDA reached 204.67M, while operating income came in at 204.67M.
| Revenue | 1.86B |
| Gross Profit | 1.52B |
| Operating Income | 204.67M |
| Pretax Income | 230.42M |
| Net Income | 244.69M |
| EBITDA | 204.67M |
| EBIT | 204.67M |
| Earnings Per Share (EPS) | 0.23 |
Balance Sheet
Beijing Aosaikang Pharmaceutical Co., Ltd. holds 2.37B in cash and equivalents against 55.31M in total debt, resulting in a net debt position of -1.51B. Total book value stands at 2.72B, with working capital of 1.75B providing operational flexibility.
| Cash & Cash Equivalents | 2.37B |
| Total Debt | 55.31M |
| Net Debt | -1.51B |
| Equity (Book Value) | 2.72B |
| Book Value Per Share | 2.98 |
| Working Capital | 1.75B |
Cash Flow
After subtracting -213.87M in capital expenditures, free cash flow totaled -213.87M - equivalent to -0.23 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -213.87M |
| Free Cash Flow | -213.87M |
| FCF Per Share | -0.23 |
Margins
Beijing Aosaikang Pharmaceutical Co., Ltd. operates with a gross margin of 81.35, reflecting its pricing power and cost economics. The operating margin of 10.99 and net profit margin of 13.14 provide insight into operational efficiency.
| Gross Margin | 81.35 |
| Operating Margin | 10.99 |
| Pretax Margin | 12.37 |
| Profit Margin | 13.14 |
| EBITDA Margin | 10.99 |
Dividends & Yields
The company's payout ratio of 47.26 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.09 |
| Dividend Yield | N/A |
| Payout Ratio | 47.26 |
| Shareholder Yield | -0.13 |
| FCF Yield | 1.47 |
Stock Splits
Beijing Aosaikang Pharmaceutical Co., Ltd.'s most recent stock split took place on May 31, 2018 with a 10:17 split ratio.
| Last Split Date | 5/31/2018 |
| Split Ratio | 10:17 |
Scores
Beijing Aosaikang Pharmaceutical Co., Ltd. posts an Altman Z-Score of 9.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 9.33 |